Management of thrombocytopenia in advanced liver disease

V. G.R. Gangireddy, P. C. Kanneganti, S. Sridhar, S. Talla, T. Coleman

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Thrombocytopenia (defined as a platelet count <150×109/L) is a wellknown complication in patients with liver cirrhosis and has been observed in 76% to 85% of patients. Significant thrombocytopenia (platelet count <50×109/L to 75×109/L) occurs in approximately 13% of patients with cirrhosis. Thrombocytopenia can negatively impact the care of patients with severe liver disease by potentially interfering with diagnostic and therapeutic procedures. Multiple factors can contribute to the development of thrombocytopenia including splenic platelet sequestration, immunological processes, bone marrow suppression by chronic viral infection, and reduced levels or activity of the hematopoietic growth factor thrombopoietin. The present review focuses on the etiologies and management options for severe thrombocytopenia in the setting of advanced liver disease.

Original languageEnglish (US)
Pages (from-to)558-564
Number of pages7
JournalCanadian Journal of Gastroenterology and Hepatology
Issue number10
StatePublished - Nov 1 2014


  • Advanced liver disease
  • Cirrhosis
  • Splenectomy
  • Splenic artery embolization
  • Thrombocytopenia
  • Thrombopoietin stmulators

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Management of thrombocytopenia in advanced liver disease'. Together they form a unique fingerprint.

Cite this